Trials / Completed
CompletedNCT01728298
A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy
A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy - The SUMMIT Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to evaluate the dose-response relationship with regards to change in immunological parameters and safety for SLITone ULTRA house dust mite mix in adult subjects with moderate to severe HDM allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SLITone ULTRA HDM immunotherapy |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2012-11-19
- Last updated
- 2014-01-22
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01728298. Inclusion in this directory is not an endorsement.